Camus S, Menéndez S, Cheok C F, Stevenson L F, Laín S, Lane D P
Department of Cell Cycle Control, Institute of Molecular and Cell Biology, Proteos, Singapore.
Oncogene. 2007 Jun 14;26(28):4059-70. doi: 10.1038/sj.onc.1210188. Epub 2007 Jan 15.
In vitro, high-risk human papillomavirus E6 proteins have been shown, in conjunction with E6-associated protein (E6AP), to mediate ubiquitination of p53 and its degradation by the 26S proteasome by a pathway that is thought to be analogous to Mdm2-mediated p53 degradation. However, differences in the requirements of E6/E6AP and Mdm2 to promote the degradation of p53, both in vivo and in vitro, suggest that these two E3 ligases may promote p53 degradation by distinct pathways. Using tools that disrupt ubiquitination and degradation, clear differences between E6- and Mdm2-mediated p53 degradation are presented. The consistent failure to fully protect p53 protein from E6-mediated degradation by disrupting the ubiquitin-degradation pathway provides the first evidence of an E6-dependent, ubiquitin-independent, p53 degradation pathway in vivo.
在体外实验中,已证实高危型人乳头瘤病毒E6蛋白与E6相关蛋白(E6AP)共同作用,通过一种被认为类似于Mdm2介导的p53降解途径,介导p53的泛素化及其被26S蛋白酶体降解。然而,E6/E6AP和Mdm2在体内和体外促进p53降解的需求存在差异,这表明这两种E3连接酶可能通过不同途径促进p53降解。利用破坏泛素化和降解的工具,揭示了E6介导的和Mdm2介导的p53降解之间的明显差异。通过破坏泛素降解途径,始终无法完全保护p53蛋白免受E6介导的降解,这为体内存在一种E6依赖性、不依赖泛素的p53降解途径提供了首个证据。